Results 31 to 40 of about 25,648 (169)

Biological aspects of mTOR in leukemia [PDF]

, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp, Gianfelici, V, Mirabilii, S, Piedimonte, M, Ricciardi, Mr, Tafuri, A.   +5 more
core   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Hematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla   +3 more
doaj   +1 more source

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine

Cell Death and Disease
Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges.
Mahesh Tambe, Sarah Unterberger, Mette C. Kriegbaum, Ida Vänttinen, Ezgi June Olgac, Markus Vähä-Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman   +8 more
doaj   +1 more source

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. [PDF]

, 2015
TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We
Amstislavskiy, V., Badarinarayan, N., Bartram, T., Baruchel, A., Basso, G., Borkhardt, A., Bornhauser, B., Bourquin, J.P., Canpolat, C., Cario, G., Cavé, H., Dakaj, D., Delorenzi, M., Dobay, M.P., Eckert, C., Ellinghaus, E., Eugster, S., Fischer, U., Forster, M., Franke, A., Frismantas, V., Ginzel, S., Gombert, M., Haas, O.A., Heidenreich, O., Hemmrich-Stanisak, G., Hezaveh, K., Hornhardt, S., Husemann, P., Höll, J.I., Kachroo, P., Korbel, J.O., Kratsch, C., Kratz, C.P., Kronnie, G.T., Lehrach, H., Marovca, B., McHardy, A.C., Moorman, A.V., Niggli, F., Panzer-Grümayer, R., Petersen, B.S., Raeder, B., Ralser, M., Rinaldi, A., Risch, T., Rosenstiel, P., Schrappe, M., Schreiber, S., Schäfer, D., Schütte, M., Stade, B., Stanulla, M., Stütz, A.M., Sultan, M., Sungalee, S., Tchinda, J., Thiele, R., Vora, A., Warnatz, H.J., Weid, N.v., Worth, C.L., Yaspo, M.L., Zaliova, M., Zhang, L., Zichner, T., Zimmermann, M.   +66 more
core   +1 more source

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor

Clinical and Translational Science
Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents.
Ahmed Hamed Salem, Rajeev M. Menon
doaj   +1 more source

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma [PDF]

, 2017
Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.
Barbieri, Eveline, Moreno-Smith, Myrthala, Shohet, Jason, Speleman, Franki, Van Goethem, Alan, Van Maerken, Tom, Vandesompele, Jo, Vasudevan, Sanjeev A, Yigit, Nurten   +8 more
core   +3 more sources

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia

Frontiers in Oncology, 2022
B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL).
Xue Yi, Nitin Jain, LaKesla R. Iles, Mary L. Ayres, William G. Wierda, Varsha Gandhi, Varsha Gandhi   +6 more
doaj   +1 more source

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardio-Oncology
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury.
Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie   +10 more
doaj   +1 more source

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia [PDF]

, 2017
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery.
Balasubramanian, Gnana P., Bandapalli, Obul R., Bornhauser, Beat C., Bourquin, Jean-Pierre, Brown, Timothy J., Cario, Gunnar, Chang, Bill H., Collins, Robert H., Delorenzi, Mauro, Diaz-Flores, Ernesto, Dobay, Maria Pamela, Dunn, Samuel H., Eckert, Cornelia, Eugster, Sabrina, Frismantas, Viktoras, Higi, Salome, Horvath, Peter, Irving, Julie A., Jenni, Silvia, Kulozik, Andreas E., Kunz, Joachim, Loh, Mignon L., Marovca, Blerim, Meisel, Roland, Muckenthaler, Martina U., Pail, Orrin, Radimerski, Thomas, Richter-Pechanska, Paulina, Rinaldi, Anna, Saha, Vaskar, Schrappe, Martin, Stanulla, Martin, Tchinda, Joelle, Tyner, Jeffrey W., Uhrig, Sebastian, Voegeli, Pamela, Von Stackelberg, Arend   +36 more
core   +1 more source

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects

Hematology
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chronic
Abdullah AlZahrani, Nada Alsuhebany, Imran K. Tailor, Abdullah M. Alrajhi   +3 more
doaj   +1 more source